SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions

Abstract Rationale Central neuropathic pain resulting from spinal cord injury is notoriously debilitating and difficult to treat with few currently available treatments. A novel molecule with intrathecal administration: Ziconotide has been approved for treatment of refractory neuropathic pain in gen...

Full description

Bibliographic Details

Published in:	Trials
Main Authors:	Andrei Brinzeu, Julien Berthiller, Nathalie Perreton, Fabien Subtil, Caroline Gervaise, Jacques Luaute, Patrick Mertens, SPIDOL Study Group
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Online Access:	https://doi.org/10.1186/s13063-024-08387-0